Personalis (PSNL) Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
- Wall Street rallies with Nasdaq up 3% as tech takes off
- Apple (AAPL) Gets a New Street High Price Target, Morgan Stanley Says iPhone Supply and App Store Could Fuel December Quarter Beat
- 'No Rival to Get Even Close' - Tesla (TSLA) Shares Soar as UBS Raises Price Target by Nearly 40%
- Intel (INTC) Shares Surge on Plans to Take Mobileye Public, Morgan Stanley Says Move a Significant Positive
- Digital World Acquisition Corp. (DWAC) Stock Jumps As U.S. Congressman Nunes Leaves to Head Trump Media
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy™.
The first patent, US Patent No. 11,142,802, entitled “Methods for Using Mosaicism in Nucleic Acids Sampled Distal to Their Origin”, issued on October 12, 2021. The ‘802 patent claims novel methods for identifying cancer mutations by comparing the sequence of cell-free nucleic acids found in the plasma to the individual’s “normal” genome, obtained from leukocytes or PBMCs, also isolated from the blood sample.
For later stage cancer patients with substantial tumor DNA in their plasma, this comparison helps discriminate true somatic variants from those of their germline genome. For earlier stage patients, with much less tumor DNA in their plasma, this method can help discriminate tumor variants from mosaicism elsewhere in the body, often referred to as CHIP.
The second patent, US Patent No. 11,155,867, entitled “Methods and Systems for Genetic Analysis”, issued on October 26, 2021. The ‘867 patent claims a novel method for the deep sequencing of a clinically-relevant exome from a cell-free nucleic acid sample. The sequencing is accomplished using capture probe techniques that target one or more genomic features, which might be missed if using just a standard exome. This technology may reveal more of the cancer biology of a patient, enabling new drug development insights or better treatment options. As the liquid biopsy field moves on from first generation small panels to next generation exome scale, and drives towards higher sensitivity, these methods will become increasingly important.
Both the ‘867 and ‘802 patents are members of broader patent families that relate to Personalis’ early work relating to exome-wide analysis and the cell-free detection of disease. These families claim priority to applications filed in 2013 and 2014, respectively.
“We are pleased that the USPTO has recognized Personalis’ continued innovation for the exome-scale, cell-free detection of nucleic acids for the detection of disease,” said Dr. Leslie Grab, VP of Intellectual Property at Personalis. “The issuance of these patents further strengthens the company’s significant intellectual property estate in the field of advanced cancer detection and analysis.” To date, Personalis has been granted 18 US and foreign patents relating to advanced genomic sequencing and analysis solutions. In addition, the company has over 25 pending US and foreign patent applications that relate to its existing advanced cancer detection platforms as well as novel research areas, including methods for interpreting genetic data generated by its platforms.
“For over ten years, Personalis has been focused on innovation,” said John West, Personalis’ Chief Executive Officer. “Our IP portfolio now spans 16 families, which cover important areas including liquid biopsy methods, personalized genetic testing, advanced biomarkers based on neoantigen characterization and HLA-loss, and more.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clean Energy Fuels (CLNE) Appoints Karine Boissy-Rousseau to its Board
- Exxon Mobil (XOM) Acquires Materia, Inc
- Seanergy Maritime (SHIP) Announces $16.6 Million Buyback of Convertible Notes, Warrants and Common Shares, as well as Open-Market Stock Purchases by the CEO
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!